2013I指南看特异性溶栓药物的使用课件

单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,*,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,单击此处编辑母版文本样式,二级,三级,四级,五级,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,AZE06044.03003,*,Ticagrelor advisory meeting So Paulo October 21,2010,Confidential AstraZeneca 2010 for internal use only,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,EF-,*,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,*,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,*,Confidential for AstraZeneca Discussion Purposes Only,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版文本样式,二级,三级,四级,五级,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,单击此处编辑母版标题样式,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,*,Confidential for AstraZeneca Discussion Purposes Only,Klicka hr fr att ndra format p bakgrundsrubriken,Klicka hr fr att ndra format p bakgrundstexten,Niv tv,Niv tre,Niv fyra,Niv fem,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Confidential AstraZeneca 2012 for internal use only,Ticagrelor advisory meeting,Atlanta,3 March 2012,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,AZE06044.03003,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Confidential AstraZeneca 2011 for internal use only,Ticagrelor advisory meeting London 2 April 2011,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,INTRODUCTION,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,UNMET NEEDS IN ACS TREATMENT,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,BRILINTA SAVES MORE LIVES THAN CLOPIDOGREL IN ACS,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,NEW AND DIFFERENT:PHARMACOKINETIC/PHARMACODYNAMIC FEATURES,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,EARLY AND ENDURING BENEFIT,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,SETTING EXPECTATIONS,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,APPROPRIATE PATIENTS,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,HOW TO PRESCRIBE,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Proprietary and Confidential.AstraZeneca 2011.Document intended for internal discussions purposes.,STENT THROMBOSIS,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,BRAND EXPRESSION,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,The BRILINTA Brand Masterfile is for internal,informational purposes only.Please refer to the Promotional Claims Guide for all approved claims related to BRILINTA.,MARKET OVERVIEW,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,The BRILINTA Brand Masterfile is for internal,informational purposes only.Please refer to the Promotional Claims Guide for all approved claims related to BRILINTA.,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,*,EF-,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,四级,五级,Confidential for AstraZeneca Discussion Purposes Only,单击此处编辑母版标题样式,单击此处编辑母版文本样式,二级,三级,